1-3 of 3
Kiyoshi Sato
Close
Sort by
Journal Articles

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

Asumi Yokota, Shinya Kimura, Satohiro Masuda, Eishi Ashihara, Junya Kuroda, Kiyoshi Sato, Yuri Kamitsuji, Eri Kawata, Yasuyuki Deguchi, Yoshimasa Urasaki, Yasuhito Terui, Martin Ruthardt, Takanori Ueda, Kiyohiko Hatake, Ken-ichi Inui, Taira Maekawa
Journal: Blood
Blood (2006) 109 (1): 306–314.
https://doi.org/10.1182/blood-2006-03-013250
Published: 2006
Includes: Supplemental data
Journal Articles

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Shinya Kimura, Haruna Naito, Hidekazu Segawa, Junya Kuroda, Takeshi Yuasa, Kiyoshi Sato, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Kimio Nasu, Tetsuo Asaki, Tomoko Niwa, Kazuko Hirabayashi, Taira Maekawa
Journal: Blood
Blood (2005) 106 (12): 3948–3954.
https://doi.org/10.1182/blood-2005-06-2209
Published: 2005
Journal Articles

Cancer Immunotherapy: Cytotoxic Activity of γδ T-Cells Expanded Ex Vivo by the Third Generation Bisphosphonate Zoledronate.

Kiyoshi Sato, Shinya Kimura, MD, Takeshi Yuasa, MD, Hiromi Wada, MD, Taira Maekawa, MD
Journal: Blood
Blood (2004) 104 (11): 1347.
https://doi.org/10.1182/blood.V104.11.1347.1347
Published: 2004